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INTRODUCTION 
The number of unwanted stray and abandoned dogs is 
increasing in the United States, and some of these free-
roaming animals cause property damage, attack other animals 
and man and spread diseases. Control of reproduction is an 
acceptable solution to the problems they create, and the 
few methods presently available for successful reproduction 
control in the canine have limited application due to cost, 
inconvenience and owner apathy. The most direct method of 
population control is to sterilize the female or inhibit 
her sexual response. Presently, the methods utilized in 
pregnancy prevention of the bitch are ovariohysterectomy, 
a mechanical device or confinement to prevent mating and 
the oral contraceptive drugs (megestrol acetate and 
mibolerone). Less costly and equally effective control 
methods need to be developed. 
To the knowledge of the author, there have been no re­
ports on the use of intravaginal or intrauterine drug 
delivery in the canine to control estrus. Intravaginal and 
intrauterine administration of estrus controlling agents has 
had limited success in a number of other animal species 
(Doyle, 1975; Casas and Chang, 1970; Faulkner and Hopwopd, 
1967; Robinson, 1965; Roche, 1976; Sreenan and Mulvehill, 
1975). 
2 
The aim of this project was to develop an intravaginal 
delivery of a contraceptive drug for the control of canine 
reproduction. To be successful, the method developed 
had to meet the following criteria; 
1) A drug delivery device had to be designed to deliver 
a suitable contraceptive drug to the animal. 
2) The delivery device had to be retainable within the 
canine vagina and cause no gross side effects. 
3) The contraceptive drug chosen for delivery had to 
be capable of diffusing across the vaginal mucosa and into 
the blood stream, without causing adverse side effects. 
4) The end effect had to result in estrus suppression. 
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LITERATURE REVIEW 
Estrous Cycle in the Bitch 
The estrous cycle (reproductive cycle) is initiated 
in the bitch at puberty. In the female Beagle, the first 
estrous cycle begins to function between 9 and 14 months of 
age (Andersen, 1970). The phases of the estrous cycle are 
proestrus, estrus, metestrus, diestrus, anestrus and some­
times pregnancy. The average duration for a complete cycle, 
in the Beagle, is 220 + 56 days (Andersen, 1970) with a 1 
month variation considered within the standard error of 
the mean cycle length (Sokolowski, Stover and Van Ravenswaay, 
1970; Jochle and Andersen, 1977). 
The first signs of proestrus are usually a sero-
sanguineous vaginal discharge accompanied by swelling of the 
vulva. The erythrocytes contained in the vaginal discharge 
are derived from the rapid proliferation of the endometrium 
by the process of diapedesis. Male attraction begins due to 
the female emission of pheromones, but the female does not 
permit coitus during this phase of the cycle. Proestrus 
may last 7 to 14 days (Andersen, 1970). 
Microscopic examination of appropriately stained vaginal 
smears may also detect the onset of proestrus. In these 
preparations, increasing cornification of the vaginal epi­
thelial cells will be seen (Roszel, 1975; Gier, 1960). In 
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early proestrus, there are many erythrocytes along with super­
ficial epithelial cells. Neutrophils and cells of deeper 
epithelial layers, parabasal and intermediate cells are also 
present during early proestrus. It has been noted that in 
mid-proestrus, the superficial cells have frayed cytoplasmic 
borders and the neutrophils are generally few in number. 
During the transition from late proestrus to early 
estrus, a vaginal smear with erythrocytes, superficial 
cells and occasionally anucleated squamate cells, is seen. 
The superficial cells are less likely to have frayed edges 
and neutrophils are absent. In early estrus, the vulva is 
swollen but less turgid and the vaginal discharge is scanty 
and less red than during the proestrus phase, 
Estrus is the period of sexual receptivity in which the 
female will assume a breeding stance and allow coitus to 
occur. The length of this phase of the reproductive cycle 
has been reported to range from 7 to 10 days (Andersen, 
1970). The smear pattern at this time represents 
a highly proliferative vaginal epithelium in response to 
estrogen. Late estrus brings the reappearance of inter­
mediate cells, superficial cells and a variable number of 
erythrocytes in the vaginal smear (Roszel, 1975) . 
Opinion is divided on what occurs after estrus, with 
some researchers characterizing the subsequent period as 
metestrus and others, diestrus. The subject is further 
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complicated by the fact that metestrus and diestrus are de­
fined in different ways (Sokolowski, 1977; Hoist and 
Phemister, 1974; McDonald, 1976; Jochle and Andersen, 1977; 
Andersen, 1970). For a possible working definition, 
metestrus can be considered as the period of corpora lutea 
development and diestrus as the period of luteal hormonal 
activity. Regardless of how the period is characterized, 
it stands that sexual receptivity ceases as estrus ends and 
metestrus begins. There is a rapid decrease in vulvular 
swelling and vaginal discharge. Early in metestrus, the 
vaginal smears have neutrophils mixed with parabasal cells, 
intermediate cells and a few superficial cells (Roszel, 
1975). Further into metestrus the superficial cells dis­
appear and increased numbers of intermediate and parabasal 
cells along with some neutrophils are seen. Smears taken 
during metestrus may contain foam cells or metestrum cells 
(Roszel, 1975) and considerable debris (Gier, 1960). 
Anestrus follows the cessation of luteal activity and 
is the phase of ovarian inactivity or sexual quiescence. 
Smears taken during this period may vary as to the pre­
dominant cell type. Neutrophils may be sparse or numerous, 
depending upon the condition of the vagina. Intermediate 
cells and parabasal cells are present and generally super­
ficial cells are absent (Roszel, 1975). 
The reproductive cycle is controlled by a complex 
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interrelationship of hormonal activity with ovarian, uterine 
and vaginal reactions. A gradual rise in follicle stimu­
lating hormone (FSH) in the blood plasma begins a few weeks 
before the onset of proestrus. Gonadotropin-releasing 
hormone (GnRH) is responsible for the release of pituitary 
FSH into the blood, but the mechanism initiating GnRH is 
unknown (Sokolowski, 1977). FSH stimulates ovarian activity 
and results in follicular development. 
Follicles approach maturity during proestrus and as 
they develop to ovulatory size, they secrete and release 
estrogens into the blood. Estrogen stimulates the vaginal 
epithelium causing cornification of the cells and thickening 
of the vaginal mucous membranes. 
As a result of estrogen stimulation there is a continu­
ation in the increase in uterine size due to the prolifera­
tion of the uterine epithelium and increased blood flow. 
The peak of blood concentration of estrogen correlates with 
the beginning of sexual receptivity by the female (Reimers 
et al., 1978; Nett et al., 1975) (see Figure Al, Appendix A). 
There is some disagreement about the level of estrogen 
(estradiol-17B) attained during late proestrus. Levels of 
14.0 + 2.4 pg/ml (Reimers et al., 1978) to 56.7 + 6.5 pg/ml 
(Nett et al., 1975) have been reported. A possible explana­
tion for the differences may be due to lipid concentration 
variations in the blood due to feeding, which affect the 
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radioimmunoassay of estrogen (Reimers et al., 1978). The 
significant point is that estrogen levels reach a peak in 
late proestrus. Present evidence indicates that ovula­
tion occurs in partial response to the high plasma estrogen 
levels (Bell, Christie and Youngglai, 1971). The estrogen 
levels decline rapidly after peaking and reach a baseline 
level by day 7 of estrus. 
Most researchers are of the opinion that rising estrogen 
levels during proestrus stimulate the release of luteinizing 
hormone releasing hormone (GnRH) and that the GnRH then 
initiates the release of luteinizing hormone (LH) from the 
pituitary. The effect of LH is to stimulate the developing 
follicle towards maturation, estrogen production and ovu­
lation. FSH and LH are both thought to have a role in 
ovulation, but ovulation will not occur without an increase 
in LH in the blood. Ovulation occurs within 24-48 hours 
after estrus begins (Sokolowski, 1977; Phemister et al., 
1973; Hoist and Phemister, 1975). Blood levels of both 
FSH (56.3 +8.7 ng/ml) and LH (1.9+1.1 ng/ml) are low 
during proestrus and coincidentally increase to a maximum 
(FSH to 167.6 +36.9 ng/ml and LH to 31.1 +4.9 ng/ml) on 
the first day of estrus (Reimers et al., 1978). LH 
rapidly declines to less than 2 ng/ml by the second day 
after the onset of estrus and remains at that level until 
the next proestrus (Reimers et al., 1978; Smith and 
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McDonald, 1974). FSH declines slowly to 69.2 + 14.7 ng/ml 
by day 6 of estrus, but does not remain at this lower level 
throughout diestrus (Reimers et al., 1978). Levels rise 
again by days 28-30 after ovulation and are reported to 
remain high through days 55-58 but no explanation is given 
for these high levels of FSH (Reimers et al., 1978). FSH 
levels then decline to a baseline level and remain until a 
few weeks preceding the next proestrus. 
Following ovulation, the follicle now without the ovum, 
becomes the corpus hemorrhagicum, which quickly develops 
into the corpus luteum. The function of the corpus luteum 
is to produce progesterone. Increasing progesterone levels 
act with the declining estrogen levels during estrus to 
promote positive sexual behavior in the female. This behavior 
consists of standing firmly, deviating the tail and dis­
playing the vulva. Progesterone stimulates the uterine 
endometrium and myometrium to undergo hypertrophy, hyper­
plasia and marked glandular development. 
Blood levels of progesterone are lowest during pro­
estrus (2.0 + 0.3 ng/ml) and have been found to increase 
gradually to approximately 22.2 + 4.5 ng/ml by the sixth 
day after estrus begins (Reimers et al., 1978). Whether or 
not the animal becomes pregnant, the progesterone levels 
remain elevated for 28-30 days following the onset of estrus 
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(Reimers et al., 1978; Concannon et al., 1977; Nett et al., 
1975; Smith and McDonald, 1974). A graduai decline in pro­
gesterone levels then ensues and by day 55-58 the level has 
dropped to 3.4 + 0.7 ng/ml (Reimers et al., 1978; Concannon 
et al., 1977; Smith and McDonald, 1974). 
Venoarterial Pathways 
In recent years, some attention has been given to 
vaginal, uterine and ovarian vasculature, especially uterine 
and ovarian vasculature. A concept involving internal 
regulation of physiological processes through local veno­
arterial pathways has evolved. The basis for this concept 
is the fact that an organ or a compartment of an organ can 
have a regulatory influence on another organ or compartment 
that is located nearby. The regulatory influence is 
accomplished through a local pathway involving the veins 
of one organ and the arteries of the other (Ginther, 1974; 
Ginther, 1976). It has been proposed that a uterine 
luteolysin is transported through a venoarterial pathway, 
which involves the veins draining the uterus and the ovarian 
artery. The luteolysin causes regression of the corpus 
luteum. The nongravid uterus produces the luteolysin, 
which passes into the uterine veins and venules. There is 
extensive contact between these veins and venules and the 
wall of the ovarian artery in animals such as the sheep 
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(Del Campo and Ginther, 1973; Mapletoft and Ginther, 1975). 
In the areas of contact the luteolysin diffuses from the veins 
and venules into the ovarian artery, where it is transported 
to the ovary to act upon the corpus luteum. Diffusion could 
be aided by the fact that the wall of the artery and vein is 
thinner in the area of apposition of,the vessels, at least 
in sheep and cattle (Ginther, 1974). 
Due to the close anatomical arrangement of arteries 
and veins near the ovary, a venoarterial pathway may exist 
in the bitch (Del Campo and Ginther, 1974). However, such a 
pathway does not seem functional in the canine, because once 
the corpus luteum is formed, progesterone is secreted 
essentially at the same levels for 60-70 days whether there 
is a pregnancy or not. Other local venoarterial pathways 
cannot be ruled out in the canine and one of these could 
possibly serve to take up a steroid from the uterus and/or 
vagina, which would in turn effect ovarian activity. 
Surgical, Prevention 
of Fertility 
A very positive method of control of reproduction is 
ovariohysterectomy. It not only provides a control of 
reproduction, but eliminates the problems associated with 
estrus and the common intrauterine diseases including 
mucometra and pyometra (Djerassi et al., 1973; Wildt and 
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Seager, 1977). Even though ovariohysterectomy is effective 
in making the pet sterile it has met with the following oppo­
sitions: 1) Some owners do not want their pet irreversibly 
sterile, and 2) some owners believe that the cost of an 
ovariohysterectomy is prohibitive (Djerassi et al., 1973; 
Wildt, Kinney and Seager, 1977). The expense of surgery 
is the most significant reason that ovariohysterectomy has 
not been utilized more fully for fertility control. Some 
cities are using public spay programs, reducing normal costs, 
but it is generally agreed that the program is only a 
partial solution to the overpopulation problem (Burns, 
1972; Faulkner, 1971; Hummer, 1975). 
Methods of performing tubal ligations with metallic 
clips or electrocautery transection of the oviducts has 
been under investigation (Wildt and Seager, 1977). Although 
this method may prevent fertilization in the female, it 
would not prevent estrus and hence the attraction of males, 
nor does it reduce the probability of future uterine prob­
lems developing. In addition, expensive laparoscopy equip­
ment ($3,000 estimated cost in 1977), is required to per­
form the tubal ligation. 
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Intravaginal Devices for 
Fertility Control 
An intravaginal device, Agrophysics Breeding Control 
Device (ABCD) is presently available from Agrophysics, 
Inc., San Francisco, California (Hauge, 1974). The device 
is designed to prevent penile insertion into the female and 
"coital-lock". Vaginal fluids are reported to drain 
posteriorly around the smooth surface of the device with no 
interference regarding normal discharges or urination (Hauge, 
1974). In addition, no adverse histopathological reactions 
or behavior changes are reported to occur while the device 
is intact. Estrus, vaginal discharge and attraction of 
males still occur while the device is in place. Retention 
of the vaginal device is dependent upon proper fitting and 
insertion at the appropriate phase of the cycle. However, 
mating will occasionally occur even with the device prop­
erly positioned. To resolve the problem, the manufacturer 
has been investigating a modified ABCD fitted with a copper 
ring (Wildt, Kinney and Seager, 1977). It is hoped that 
ionized copper will cause the vaginal secretions to be 
spermicidal. 
13 
Pharmacological Control of 
Fertility 
A number of oral and injectable contraceptive drugs 
have been studied and found to control fertility, but they 
often cause pathological changes in the uterus making an 
ovariohysterectomy necessary. All known exogenous pro­
gestogens can cause cystic endometrial hyperplasia, endo­
metritis and mucometra (Wildt and Seager, 1977). The fol­
lowing progestogens have been studied; Progesterone (Bell 
and Christie, 1971; Capel-Edwards et al., 1973; Christie 
and Bell, 1970; Sokolowski, 1974; Cox, 1970); Medroxy­
progesterone Acetate (MAP) (Bell and Christie, 1971; Anderson 
et al., 1965; Brodey and Fidler, 1966; Bryan, 1973); 17a-
acetoxyprogesterone (Bell and Christie, 1971; Bryan, 1960); 
Norethisterone Acetate (Cox, 1970; Hainan, 1965; Prole, 1974a; 
Prole, 1974b); Delmadinone Acetate (Stabenfeldt, 1974); 
Melengestrol Acetate (Zimbelman et al., 1970); Chlormadinone 
(Nelson et al., 1972); Megestrol Acetate (Ovaban) (Bell and 
Christie, 1971; Sokolowski, 1974; Cox, 1970; Sobering Corp., 
1975); and Proligestone (Van Os and Oldenkamp, 1978). 
Of these progestogens, only megestrol acetate (Ovaban) 
used for the postponement or prevention of estrus in the 
canine has been approved for commercial use in the United 
States. Megestrol acetate is administered orally. The 
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mechanism of action is unknown but some believe it acts by 
inhibiting the production and release of hormones and/or 
local prevention of ovarian follicle growth, estrogen 
secretion and ovulation (Sobering Corp., 1975) . Megestrol 
acetate has been approved for a maximum of 32 days continuous 
use and should not be repeated for more than two consecutive 
estrus cycles. Excessive use of the drug may cause cystic 
endometrial hyperplasia (Van Os and Oldenkamp, 1978). 
Estrus inhibition with minimal side effects occurs 
with subcutaneous androgen implants, such as testosterone 
(Simmons and Hamner, 1973). Anestrus was maintained for up 
to 840 days, in 60 females studied. The disadvantages of 
the testosterone implants include the possible need for more 
than one implant, depending upon the weight of the animal, 
and the need for general anesthesia to permit surgical 
implantation in the subcutaneous tissue of the flank. In 
addition, there may be some masculinization including 
enlargement of the clitoris and increased vaginal discharge 
during the implantation period, but these effects are con­
sidered minimal. The precise mechanism of action of testos­
terone is unknown, but it is thought to suppress the 
hypothalamic-pituitary gonadotrophin release system 
(Simmons and Hamner, 1973) . 
Mibolerone (173-hydroxy-7a, 17-dimethylestr-4-en-3-one) 
an androgenic anabolic steroid has been used orally as a 
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treatment for preventing estrus and found to have minimal 
adverse side effects (Sokolowski, 1974). The drug is marketed 
for oral administration by the Upjohn Company (Kalamazoo, 
R Michigan) under the trade name Cheque. Estrus is inhibited 
only for the duration of a daily dosage, which, to be 
effective, must be initiated prior to the beginning of 
proestrus. The daily dose level is calculated according to 
the body weight of the bitch, with some breed variations 
(Sokolowski, 1976, 1978a). 
Primary and secondary follicular development on the 
ovary still proceeds when mibolerone is given, but the 
follicles do not mature to ovulatory size. The LH surge is 
blocked by mibolerone through an unknown mechanism (Upjohn 
Company, 1979; Reimers, 1978; Sokolowski, 1976). Thus, 
estrus, ovulation and corpus luteum formation are prevented 
during the administration of mibolerone (Sokolowski, 1976; 
Reimers, 1978). 
Mibolerone is rapidly metabolized and the breakdown 
products are excreted in the urine and feces. The highest 
tissue concentrations of mibolerone have been found in the 
liver, anal glands and reproductive organs (Sokolowski, 
1976) . 
The biological effects of mibolerone have not been 
thought to be detrimental to the animal's health either 
during or after treatment (Sokolowski, 1976, 1978b; Sokolowski 
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and Gang, 1977). Beagles have been subjected to 30 yg/day, 
90 yg/day and 200 yg/day drug dose levels for up to 730 
days. The normal dose of mibolerone to control estrus in 
the beagle was 30 yg/day, but treatment levels of 200 yg/day 
for 730 days were not harmful (Sokolowski and Ceng, 1977). 
Vaginal irritation and clitoral enlargement were more promi­
nent in the immature than in mature females treated with 
200 yg/day for 730 days (Sokolowski, 1978b). A vaginal dis­
charge consisting of a white viscid liquid containing 
leucocytes has been associated with vaginal irritation and 
clitoral enlargement. Periodic episodes of excessive 
lacrimation also occurred in some test animalsl Evalua­
tions including clinical chemistry, hematology, urinalysis, 
gross pathology and histopathology have shown no drug 
related toxic effects. The only drug related effects in 
the female have occurred when daily oral administration has 
been at 3,000 yg and above (Sokolowski, 1976, 1978b). These 
high mibolerone treatment levels have produced a reduction 
in stainable lipid in the adrenal cortices, a thickening of 
the myometrium and endometrium and enlargement of the 
clitoris. 
Mibolerone, administered orally, is presently approved 
for a two year period of continuous use in the female canine 
for the control of estrus. 
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Pharmacological Inducement of 
Asexuality 
Sterility has been induced in young female mice and 
rats by single injections of testosterone propionate 
(Barraclough, 1961). 
Female neonate puppies have been injected with testos­
terone propionate, depo-testosterone cyclopentylpropionate, 
or medroxyprogesterone acetate to inhibit sexual maturation 
and induce sterility. These androgen and progestin deriva­
tives were ineffective in inducing sterility or delaying age 
of first estrus in the canine because hypothalamic differentia­
tion occurs before birth in this animal (Zimbelman and Lauder­
dale, 1973). 
Immunological Control of 
Canine Fertility 
Immunological methods for neutralizing endogenous 
hormone have met with limited success as a means for sup­
pressing the reproductive function. Female beagles im­
munized with human chorionic gonadotropin (HCG) developed 
antibodies to the HCG. Unfortunately, the antibodies were 
not cross-reactive with the beagle pituitary gonadotrophins 
and reproductive impairment was not produced (Al-Kafawi 
et al., 1974). Immunization of female beagles with bovine 
LH or ovine gonadotropins has stimulated an immunological 
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response producing a temporary reproductive failure, but 
additional injections of bovine LH or ovine gonadotropins 
have had decreased effectiveness (Faulkner et al., 1975). 
Irradiation for Fertility 
Control 
Single and multiple irradiation (x-ray treatment) 
applied directly on surgically exposed ovaries has produced 
infertility, which in some cases was reversible (Lee and 
Carlson, 1965, 1967). Whole-body x-ray treatment during 
early puppyhood (birth to two months of age) has provided 
some success in causing abnormal follicles in the ovaries 
but not so in older dogs (Andersen and Simpson, 1970). 
Multiple x-ray treatments are necessary to produce infertility 
and cannot be considered practical or economical as a fertility 
control method in dogs. 
Implantable Drug Delivery 
Systems 
The concept of implantable drug delivery systems has 
been reported in use as early as 1937, when R. Deansley and 
A. S. Parkes subcutaneously implanted compressed pure 
crystalline estrone in chickens (capons) (Blackshear, 1979). 
Silicone-rubber capsules are the simplest of the 
delivery systems. They are composed of a silicone rubber 
capsule which serves as a diffusible membrane for the drug 
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contained within it. Drugs of low molecular weight and many 
hormonal preparations diffuse readily through the silicone 
(Kind et al., 1968; Dziuk and Cook, 1966; Doyle, 1975). 
The silicone-rubber capsules have been found to produce 
little to no inflammation of body tissue and are considered 
very acceptable for implantation. 
An implantable infusion pump (trade name Infusaid) 
is presently being manufactured and is considered by some 
people to be an improvement on devices that deliver through 
membranes (Blackshear, 1979). The Infusaid consists of a 
cylindrical disk about the size of an ice-hockey puck. The 
cylindrical disk is divided inside by a cylindrical bellows, 
forming an inner and outer chamber. Medication is contained 
in the inner chamber and a fluorocarbon in a liquid-vapor 
combination is in the outer chamber. The operation of the 
pump is based on the concept that a liquid in equilibrium 
with its vapor phase will exert a constant vapor pressure 
at a given temperature, regardless of volume. Pressure 
created in the outer chamber pushes against the bellows, 
which then forces the medication through a delivery cannula 
connecting the inner chamber and a vein. The cylindrical 
disk including bellows is made of titanium, which is im­
permeable, light in weight and compatible with body 
tissues. 
An osmotic dispenser, patented in 1975 by T. Higuchi, 
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has been developed by the Alza Corporation, Palo Alto, Cali-
TM fornia, into the now commercially available Alzet 
Osmotic Minipiimp. The Higuchi-Alza Minipump consists of an 
expandable solution-containing chamber which has an osmotic 
membrane exposed to body fluids, a drug reservoir, and a 
flow control "capillary" tube to permit the slow discharge 
of the drug as the expandable chamber increases in volume 
due to osmotic pressure (Higuchi, 1975; Yates, 1977). The 
Minipump has been used successfully as a subcutaneous im­
plant infusing several different drugs, individually, over a 
four day period (Bowers and Folkers, 1976). 
A more complex implantable capsule for delivering 
drugs has the unique feature of a magnetic "switch" (Merrill, 
1972). Only a portion of the capsule wall is constructed 
of a drug-permeable material with the remainder of the 
capsule wall nonpermeable to the drug. Utilizing an 
external magnetic force, an inner nonpermeable, magnetically-
moveable wall is activated to expose the drug to the per­
meable membrane allowing diffusion into the permeable 
membrane and subsequently into the body. Drug diffusion 
is stopped by reversing the external magnetic force, which 
moves the inner nonpermeable wall between the drug and the 
permeable membrane. 
For implantation, a ballistically implantable projectile 
has been adapted to carry drugs into an animal and thereafter 
21 
provide sustained release of the drug (Drake and Paul, 1976). 
The bullet shaped ballistic projectile is designed to contain 
a drug within a cylindrical cavity in the basilar portion 
of the projectile. The walls of the projectile may be 
composed of a microporous, insoluble material, such as, 
polysiloxane or a soluble material, such as, gelatin or 
hydroxypropyl cellulose in order to provide a sustained 
release of the drug within the animal. 
An intravaginal device for dispensing drugs to human 
females has been designed (Tillmann, 1970). The device 
is a hollow rod having a rounded cap with small apertures 
at one end through which the drug is delivered. The drug 
is forced through the small apertures by pressure from a 
dosing piston which has some similarity to the plunger found 
in a syringe. The stem of this dosing piston is designed 
as a feed gear which can be activated to deliver a specific 
amount of drug. Finger or thumb pressure on the base end 
of the device causes the feed gear to push forward and hence 
dispense the desired amount of drug. This device remains 
intravaginal only during the time required for each drug 
dispensation. 
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Basic Steroid Diffusion Through 
Silicone-Rubber 
A great quantity of research on contraceptive drugs 
has established the fact that reproductive steroid hormones 
do pass through silicone-rubber (Kincl et al., 1968; Dziuk 
and Cook, 1966; Doyle, 1975; Tatum, 1970). Transmission of 
a steroid through a silicone-rubber membrane free from flaws 
occurs by an activated diffusion process (Dennis and Larson, 
1977). The steroid first dissolves in the surface layers, 
followed by migration through the silicone-rubber membrane 
under a concentration gradient, and then is detached from 
the low concentration surface. The diffusion mechanism 
involves a concept of segmental polymer motion to form a 
free volume in the membrane; the available free volume is 
then occupied by a steroid molecule, which then migrates 
across and detaches from the opposite side. 
Permeability is a function of both the properties of 
the diffusing molecule and of the silicone-rubber. Molecular 
size, shape, polarity and solubility parameters of the dif­
fusing molecule greatly affect their transmission rate 
(Dennis and Larson, 1977). Crystallization, degree of cross-
linking and rigidity of the silicone-rubber backbone also 
influence diffusion (Dennis and Larson, 1977). Other factors 
having considerable effect on diffusion are; 1) concentra­
tion of the diffusing molecules, 2) temperature, 3) membrane 
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thickness, and 4) membrane surface area exposed to the 
diffusing molecules. 
Steroid diffusion across a silicone-rubber membrane 
has been found to be proportional to the thickness and area 
of the membrane (Kind et al., 1968). Increasing the area 
exposed to the steroid results in a proportionate increase 
in diffusion. Increasing the thickness of the membrane 
causes a proportionate decrease in diffusion. The diffusion 
rate (at standard temperature and pressure) has been expressed 
as yg of steroid/time period/membrane area exposed/membrane 
thickness (Kind et al., 1968). 
Temperature effect on the rate of diffusion is dependent 
on the nature of the material diffused. If the diffusing 
material consists of relatively small and nonpolar molecules, 
the permeability of silicone-rubber decreases with increasing 
temperature due to decreasing solubility (Dennis and Larson, 
1977) . Permeability increases directly with increasing 
temperature when the diffusing molecules undergo certain 
conditions of high energy of activation for diffusion 
(Dennis and Larson, 1977). 
24 
Intravaginal and Intrauterine Delivery of 
Drugs for Estrus Control 
To the knowledge of the author, intravaginal or intra­
uterine drug delivery systems have not been used for canine 
estrus control. Estrus controlling drugs delivered by the 
intravaginal or intrauterine route have had limited success 
in a number of other animal species. 
Vaginally inserted polyurethane sponges impregnated 
with a progestogen have successfully controlled the onset 
of estrus and ovulation in the cyclic ewe (Robinson, 1965). 
Estrus and ovulation were blocked while the impregnated 
sponges were intravaginal. Upon removal of the sponges, 
estrus and ovulation began 2-3 days later in the mature 
ewe. The sponges produced vaginitis but this had no effect 
on fertility. 
Intravaginal suppositories impregnated with 9a-fluoro-
3 y-lip-hydroxy-lVa-acetoxyprogesterone,1, 2- H have been 
inserted into a number of ewes and drug uptake monitored 
(Faulkner and Hopwood, 1967). Between 12 and 24 percent of 
the drug was found to be absorbed from the suppository. 
Progestogen-impregnated vaginal suppositories inserted 
for 20 days have been used to synchronize estrus in cattle. 
Suppository retention has been low and subnormal fertility 
rates have been reported for the first estrus following the 
treatment period (Sreenan, 1974, 1975). A follow-up study 
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(Sreenan and Mulvehill, 1975) compared the suppository treat­
ment for 10 and 20 days along with an intramuscular injection 
of progesterone and estradiol benzoate at the time of in­
sertion. Suppository retention was above 93 percent during 
the 10-day period, but decreased to 86 percent over the 20-
day period. Fertility at first estrus was found to be better 
after the 10-day intravaginal treatment than after the 20-day 
intravaginal treatment. 
A silastic coil impregnated with progesterone has been 
placed intravaginally for 12 continuous days in the bovine. 
High coil retention, controlled estrus and normal fertility 
were the results of the 12-day treatment (Roche, 1976). 
In rats (Doyle, 1975), monkeys and humans (Scommegna 
et al., 1970), intrauterine delivery of progestins has been 
investigated mainly for their effect in decreasing uterine 
motility and thus improving the retention of existing intra­
uterine contraceptive devices (lUD's). In the rat, the 
primary aim was to establish which compounds might have 
potential for human use in retaining lUD's. All the pro­
gestins tested were effective in enhancing retention of the 
silicone-rubber lUD's with melengestrol acetate being most 
effective. 
Small doses of progestins have been shown to be contra­
ceptive without suppressing ovulation (Scommegna et al.. 
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1970). The normal menstrual patterns of primates were not 
significantly altered, even though endometrial changes did 
take place, therefore, it has been suggested that implanta­
tion may be prevented by a slight change in hormonal balance 
of the endometrium, hence providing successful contraception 
(Scommegna et al., 1970). 
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MATERIALS AND METHODS 
Experimental Design and Animals 
A completely randomized experiment involving 20 female 
beagles (Canis familiaris) of approximately the same size 
and weight were used to evaluate an intravaginal drug 
delivery device. Seventeen females with normal and known 
estrous cycles were obtained from the Gaines' Gerontology 
Beagle Colony at Iowa State University. An earlier experi­
ment involving Control, High and Medium dietary protein 
levels utilized the same females that were used in this study. 
Three additional female beagles with normal estrous cycles 
were brought into this colony, 24 May 1978, from Ridglan 
Farms.^ 
Colony estrous records were evaluated and experimental 
subjects were selected on the basis of regular estrous 
cycles. These animals were then randomly assigned to treated 
(15 females) or control (5 females) groups. An additional 
10 females within the colony were monitored for cycle regu­
larity throughout the study and for accuracy of estrus 
prediction. 
Test animals receiving delivery devices had the devices 
placed intravaginally approximately one month before the 
^Ridglan Research Farms, Inc., 301 West Main Street, 
Mt. Horeb, Wisconsin. 
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expected estrus. Each delivery device remained intravaginally 
for a three month period and was then removed. Fifteen fe­
males were treated with mibolerone in the delivery device 
and 5 females were given "placebo" delivery devices. 
Housing for the 
.Beagles 
All animals were housed in the facilities provided for 
the Gerontology Beagle Colony. Prior to 1 November 1978, 
they were kept in 5• by 10' wire enclosed pens within an 
unused dairy barn. Each pen contained a "dog house", 
which served as a sleeping and resting area for the animals. 
The floor of each "dog house" was triangular shaped (4' by 
4' by 5.6') and had an 8" support leg at each corner. Sides 
of the "dog house" were 24" high, capped with a flat roof 
bearing the same dimensions as the floor. Food and water 
were available continuously in each pen. All female beagles 
were moved from the dairy barn facility on 1 November 1978 to 
a newly constructed building designed for the colony. Pens 
in the new building were 4' by 8' with food and water avail­
able continuously. Individual pens contained 3 or 4 
beagles. 
29 
Drug Diffusion Rate of the 
Delivery Device 
A number of delivery designs were discussed with Drs. 
1 2 Evans and Hembrough before the evolution of the slow-
releasing drug-delivery device (Figure 1) used in this study. 
In tests by investigators at the Upjohn Company^, silastic 
capsules had been used to deliver mibolerone subcutaneously. 
These capsules were found unsatisfactory in the delivery 
control of mibolerone. This author was unable to acquire 
information regarding mibolerone diffusion across the 
silastic membranes. As a result, accurate mibolerone dif­
fusion rates through silastic membranes were unknown to the 
author at the beginning of this study. The theoretical 
estimate for the mibolerone diffusion rate was assumed to 
be equal to that reported for testosterone, 317 yg/24 hrs/100 
mm^/0.1 mm (Kind et al., 1968). 
The oral mibolerone dosage for the beagle is 30 yg/day 
to prevent estrus. It was calculated (based upon the above 
equation for testosterone) that a silastic membrane 1 mm 
2 thick with a 20 mm surface area should deliver 6 yg of 
mibolerone/day. The spring pressure constructed into the 
^Lawrence E. Evans, D.V.M., Ph.D., Department of Veteri­
nary Clinical Science, Iowa State University, Ames, Iowa. 
^Frederick Hembrough, D.V.M., Ph.D., Department of 
Veterinary Pharmacology and Physiology, Iowa State University 
Ames, Iowa. 
3 
James Sokolowski, D.V.M., Reproduction Research, The 
Upjohn Company, Kalamazoo, Michigan. 
Figure 1. The schematic design of the intravaginal slow-releasing drug-delivery 
device 
1) Delivery end of the device 
2) Dacron re-enforced silastic membrane 
3) Retaining ring 
4) Cylindrical housing 
5) Medical grade silastic tubing covering the cylindrical housing 
6) Rubber plunger 
7) Steel coiled spring 
8) Plug, sealing nondelivery end 
9) Retrieval ring, when looped through the walls of housing, 
helps retain steel coiled spring 
10) Silastic "fingers" 
31 
32 
delivery device was assumed to have some effect on mibo-
lerone diffusion. The pressure created in the delivery 
device was known to exceed 800 mm Hg (Table 1). As a result, 
the decision was made to consider the spring pressure effect 
on diffusion as a factor of 10, until proven otherwise. The 
6 yg was then multiplied by 10 to take into consideration 
the spring pressure constructed into the device. So, in 
theory, the delivery device (U.S. Patent application No. 
124, 542) for this study was designed to constantly deliver 
approximately 60 yg of mibolerone/day, double the normal 
effective oral dose. 
Delivery Device 
Construction 
The drug delivery device was hand constructed and con­
formed to the design shown in Figure 1. A 3 ml disposable, 
nontoxic, nonpyrogenic, polypropylene syringe^ was cut down 
to 2.5 ml for the cylindrical housing. The delivery end 
was melted, flattened and cooled. Then 5, 1 mm diameter 
holes were drilled through its face. . The inside face of 
the delivery end was then covered with an 8 mm diameter by 
2 1 mm thick dacron re-enforced silastic sheeting held in 
^B-D Disposable 3 cc Syringe, Becton-Dickinson Division, 
Becton, Dickson and Company, Rutherford, New Jersey. 
2 
Re-enforced Silastic Sheeting No. 501-7, Dow-Corning 
Chemical Company, Midland, Michigan. 
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place with a plastic retaining ring (I.D. 5 mm). Eight-
tenths ml of 0.00876 grams of mibolerone crystals in 95% 
ethanol was then added to the chamber and secured in place 
by the original plunger, which was modified by shortening 
the plastic stem to fit into the new housing. A steel coil 
spring was placed behind the plunger and locked into the 
chamber by looping the retrieval ring through the housing. 
Scraps of polypropylene, cut earlier from the syringe, 
were melted and used to seal the end of the syringe containing 
the retrieval ring. After cleansing with 75% ethanol, the 
entire delivery device was inserted into an 8 cm piece of 
T 
Sterile silastic tubing . Excess tubing was allowed to 
extend beyond the retrieval ring at the nondelivery end. 
The tubing beyond the housing was then cut into quarters 
(see design in Figure 1), creating 4 silastic "fingers" 
which served to retain the delivery device within the vagina. 
The tubing was attached to the housing at the base of the 
2 
retrieval ring by silicone-rubber adhesive , which required 
12 hours to cure. The device was cold sterilized with 75% 
ethanol as the final step in preparing the device for in-
sertion into the vagina. 
^Medical Grade Silastic Rubing (I.D. 3/8", O.D. 1/2"), 
Dow-Corning Chemical Company, Midland, Michigan. 
2 
Medical Grade Silastic Adhesive No. 891, Dow-Corning 
Chemical Company, Midland, Michigan. 
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Delivery Device Internal 
Pressure 
The slow-releasing drug-delivery device (Figure 1) in­
cluded a compression spring which exerted pressure on the 
mibolerone-ethanol solution contained within the device. 
Pressure was measured in 4 of the delivery devices with a 
1 2 Statham transducer and recorded on a Beckman polygraph . In 
all 4 of the delivery devices, the initial pressure was 
measured with 0.8 ml of 95% ethanol in each of the devices. 
In 2 of these delivery devices, the pressure was measured 
with 0.2 ml of ethanol remaining and this was considered 
the end pressure. 
Preparation of the Drug 
Solution 
The drug solution was prepared by weighing (on an 
analytical balance^) 0.05475 grams of mibolerone crystals. 
The crystals were then dissolved in 5 ml of 95% ethanol. 
Each delivery device used in the mibolerone treated animals 
contained 0.8 ml of this solution or a similarly prepared 
solution. 
^Statham P23dB, Statham Instrument, Inc., Oxnard, Calif. 
2 Beckman R611 Dynograph, Beckman Instrument, Inc., 
Schiller Park, Illinois. 
^Sartorius Balance Model No. 2400, Sartorius Balances 
Division, Brinkmann Instruments Inc., Westbury, New York. 
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Delivery Device Insertion 
and Removal 
Insertion of the drug delivery device was a very simple 
process. The conscious animal was maintained in a standing 
position by one person placing one hand under the abdomen 
and the other hand holding the tail erect. A second person 
clamped the retrieval ring on the delivery device with a 
Bozeman uterine dressing forcep (Figure 2) and dipped the 
delivery end into a jar of nitrofurazone dressing. The 
nitrofurazone was allowed to lightly cover one inch of the 
delivery end. The vulva of the beagle was then cleansed 
with a solution of 75% ethanol and 25% chlorhexidine hydro­
chloride. Next, with the fingers of one hand the labia 
were separated and the delivery device inserted, delivery 
end first (Figure 3). Gentle dorsocephalad pressure moved 
the device to a position dorsal to the pubic bone. The 
directional pressure was then changed to cephalad, moving 
the device to a position cranial to the pubic bone. The 
forcep was then released and removed. The same insertion 
procedure was accomplished by one person with five of the 
animals, without restraint. 
^Bozeman Uterine Dressing Forcep, Arista Surgical 
Supply Company, Inc., New York, New York. 
Figure 2. Uterine dressing forcep clamped to the retrieval 
ring of the intravaginal drug delivery device 
Figure 3. The drug delivery device was easily and gently 
inserted into the vaginal canal 
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The procedure for removing the device underwent several 
changes during the experimental period. In the first two 
animals, the delivery devices each had a 3" piece of 2-0 
suture material attached to the retrieval ring (Figure 4). 
One female was able to remove the device herself, so attach­
ment of suture material was discontinued. As an alternative 
procedure, the uterine dressing forcep was used unsuccessfully 
in several attempts to clasp the delivery device and pull 
it out. This method presented the danger of clamping the 
vaginal mucosal lining along with the delivery device hence 
tearing or crushing the tissue. A third removal technique 
involved hooking the delivery device retrieval ring with a 
modified Covault spay hook^. This method was met with 
considerable resistance from the animal, caused some vaginal 
bleeding and took approximately 10 minutes under the best of 
conditions. An improved removal procedure (Figures 6-11), 
used on 3 animals, has been most effective and practical. 
2 
.Zin anoscope (Figure 5) , with a 127 mm speculum length and 
a 14 mm aperture was inserted into the vagina to allow 
easy viewing of the retrieval ring (Figure 9). The spay 
hook was inserted through the anoscope and the retrieval 
^Covault Spay Hook, Arista Surgical Supply Company, 
Inc., New York, New York. 
2 Long Speculum Anoscope No. 39514, Welch Allyn, Inc., 
Skaneateles Falls, New York. 
Figure 4. The initial drug delivery device, used in this 
study, incorporated a piece of suture material 
to assist removal 

Figure 5. The long speculum anoscope and spay hook were 
valuable tools utilized in the removal of the 
delivery device 
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Figure 6. Beagle X03 had received a drug delivery device 
4 weeks earlier (note - no vaginal discharge) 
Figure 7. Delivery device removal from Beagle X03. In­
sertion of the anoscope into the vaginal canal 

Figure 8. Delivery device removal from Beagle X03. The 
spay hook was inserted through the anoscope 
and attached to the retrieval ring of the 
delivery device 
Figure 9. Delivery device removal from Beagle X0 3. 
The retrieval ring on the delivery device was 
easily seen through the anoscope, permitting 
quick attachment of the spay hook 

Figure 10. Delivery device 
delivery device 
of the anoscope 
removal from Beagle X03. The 
was held firmly against the end 
as removal began 
Figure 11. Delivery device 
delivery device 
against the end 
removal from Beagle X03. The 
was removed while held firmly 
of the anoscope 
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ring hooked. The delivery device was held firmly against 
the end of the anoscope as both were removed from the vagina. 
This procedure was accomplished by one individual on a 
fully conscious animal in less than one minute. 
Plasma Collection for the Analysis of Mibolerone 
and/or Progesterone Levels 
Blood samples (approximately 8 ml/sample) were taken 
once every two weeks during the test period. Blood was 
collected from the right or left cephalic vein into 
heparinized vacutainers (10 ml containers) via a 20 gauge 
2 bleeding needle. The blood was then centrifuged at 2100 
rpm for 15 minutes and the plasma was pipetted, transferred 
to 3.5 ml plastic vials, and frozen until radioimmunoassayed 
for mibolerone or progesterone. 
Mibolerone Assay 
3 
Frozen plasma samples were sent to the Upjohn Company 
for analysis of mibolerone levels. The assay used a double 
antibody radioimmunoassay technique as described by 
Krzeminski et al. (1978). The sensitivity of the assay 
^B-D Heparinized Vacutainer, 10 ml volume, Becton-
Dickinson Division, Becton, Dickinson and Company, Ruther­
ford, New Jersey. 
2Model CL, lEC Clinical Centrifuge, Damon/IEC Division, 
Needham Heights, Massachusetts. 
3jenaay M. Brown (D.V.M), Reproduction Research, The 
Upjohn Company, Kalamazoo, Michigan. 
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was 1.8 parts per billion. 
Progesterone Assay 
The radioimmunoassay procedure for progesterone was 
initiated by pipetting 100 pi of thawed plasma sample and 
400 yl of Tris buffer into a test tube. To this tube, 4.5 
ml of petroleum ether was added. The test tube was then 
tightly capped and shaken for 15 minutes. . Following the 
period of shaking, the test tube was placed in a dry ice-
methanol bath until the water layer in the tube froze. The 
petroleum ether phase was decanted into another test tube 
which then was placed in a 40°C water bath. The petroleum 
ether evaporated and the test tube was removed from the bath. 
Next, 100 yl of Tris buffer was added to the test tube and 
vortexed vigorously. The progesterone extraction from the 
plasma was completed at this point. The assay continued 
3 
with 0.4 ml of the antibody and 0.1 ml of the tracer ( H-
progesterone) simultaneously added to the test tube and 
gently vortexed. The test tube was covered with paraffin 
and incubated overnight in a "cold room". 
The final stages of the assay were completed by adding 
0.2 ml of charcoal-dextran with vortexing of the test tube. 
Fifteen minutes later the test tube was centrifuged at 3000 
rpm for 10 minutes. Next, a 0.5 ml sample of the assay 
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supernatant along with 4.5 ml of a scintillation cocktail 
was pipetted into a scintillation vial. Radioactivity for 
the sample was monitored on the tritium channel of a liquid 
scintillation counter and recorded. The resulting sample 
counts were compared with progesterone standards that were 
assayed simultaneously with this group of samples. 
The complete procedure for progesterone analysis is 
included in Appendix B. 
Vaginal Smears to Determine the Phase 
of the Estrous Cycle 
Smears of cells from the vaginal mucosa were taken 
weekly from each animal throughout the test period and for 
4 weeks beyond the end of the test period. First, the vulva 
of the female was cleansed with a 75% ethanol and 25% 
chlorhexidine hydrochloride solution. The labia then were 
separated with one hand and a sterile cotton swab was intro­
duced into the dorsal aspect of the labial commissure with 
the other hand. The swab was gently inserted (approximately 
10 cm) through the vaginal vestibule, past the pelvic brim 
and along the craniodorsal aspect of the vagina. The swab 
was rotated to free and collect cells from the mucosal lining 
and then was gently withdrawn. After withdrawal, the swab 
was rolled onto a precleaned microscope slide. The vaginal 
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cells then were stained with Wright's stain in an Ames 
Hema-Tek slide stainer^ and cell types were evaluated 
microscopically. 
Daily, Physical Examination 
To assist in the evaluation for estrus during the test 
period, daily physical examinations for vaginal discharge 
and labial swelling were performed. Behavior also was 
observed during this daily examination. Digital stimulation 
was applied to the dorsal aspect of the lumbar area to see 
if a breeding stance would be taken. Observations were also 
made to determine whether the treated female was "teasing" 
other females in the pen and whether the other females were 
trying to mount the treated female. Animals were checked 
daily for ocular discharge that is known to occur with exces 
sive doses of mibolerone. 
Estrus Resumption after 
Treatment 
Each treated female was checked for estrus 3 times 
weekly, following treatment termination. To confirm 
suspected estrus, vaginal smears and/or testing of plasma 
progesterone levels were evaluated. 
^Ames Hema-Tek Slide Stainer, Miles Laboratory, Inc., 
Elkhart, Indiana. 
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Vaginal Examination with 
a Cystoscope 
A cystoscope^ was used to examine the vaginal tract of 
three females, containing a delivery device, to check for 
the presence of any excessive exudate, inflammation and/or 
hyperemia. Two beagles were anesthetized with thiamylal 
sodium (6 mg/lb) and their vaginal tracts were visually in­
spected with the use of the cystoscope. The delivery device 
was removed using an anoscope (Figures 6-11) and the vagina 
re-inspected using the cystoscope. Photographs were taken 
2 
with a 35 mm Pentax camera attached to the cystoscope. A 
third beagle was examined using the cystoscope and the 
anoscope, while fully conscious throughout the examination. 
3 
Photographs were taken with a 35 mm Olympus camera while 
viewing through the anoscope. 
Body Weight Data 
Collection 
Androgens are known to be anabolic (tissue building), 
so body weights were obtained weekly for each animal in order 
to evaluate whether or not this was a problem in mibolerone 
^Model FCB 1000 Fiber Optic, American Cystoscope Makers 
Inc., Pelham Manor, New York. 
2 Model ES Pentax Camera, Honeywell, Littleton, Colorado. 
3 
Model OM-1 Olympus Camera with 50 mm lens, Olympus 
Optical Co., Ltd., Tokyo, Japan. 
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treatment. Weights were recorded beginning one month before 
and continued for one month beyond the test period. Weight 
was recorded to the nearest half pound. 
Statistics 
A standard t-test was computed for progesterone levels 
to determine if there was a difference between treated and 
nontreated animals. 
An analysis of variance was computed for body weight 
gain and loss data. The analysis was undertaken to provide 
answers for the following questions; 
1) Was there a difference in weight gain or loss 
between mibolerone treated animals versus nontreated animals? 
2) Was there a difference in weight gain or loss between 
mibolerone treated versus nontreated females on different 
levels of the protein diet? 
3) Did age have an effect on weight gain or loss in 
treated versus nontreated animals? 
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RESULTS 
Delivery Device Internal 
Pressure 
The internal pressure recorded from within four delivery 
devices ranged from 800 mm Hg to 870 mm Hg. Two of the 
devices had both initial and end delivery pressures recorded, 
the other two had just the initial delivery pressure re­
corded . 
Table 1. Delivery device internal pressure (in mm Hg) 
Delivery Initial End 
device pressure pressure 
1 800 800 
2 870 870 
3 800 -
4 840 -
Body Weight 
Age of the beagles, dietary protein, treatment, initial 
body weight and body weight at the end of six weeks are 
summarized in Table 2. The data in Table 2 were used for 
the analysis of variance to evaluate treatment effects on 
body weight. A six-week time period was chosen because the 
delivery devices were known to contain a portion of the 
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Table 2. The data for treatment effect on body weight 
^ ^ . Initial Six week 
Beagle Treatment weight weight 
(years) level (lbs, (lbs, 
218 9 control mibolerone 25.0 22.0 
427 10 control mibolerone 21.5 21.0 
S62 5 medium mibolerone 25.5 24.5 
YQIl 7 control mibolerone 29.5 27.0 
PQY2 6 control mibolerone 31.0 30.0 
VDU3 5 control mibolerone 24.0 25.0 
867 7 control mibolerone 30.5 30,0 
S57 5 high mibolerone 26.0 27.0 
poll 7 control mibolerone 20.0 20.0 
S54 5 high mibolerone 24.0 24.5 
U17 4 high mibolerone 26.0 26.5 
S42 5 medium mibolerone 21.0 21.0 
U06 5 medium mibolerone 32.0 31.0 
U09 4 medium mibolerone 28.0 27.0 
X02 3 high mibolerone 36.0 38.0 
X03 3 high mibolerone 25.0 25.0 
S31 5 medium control 18.0 18.0 
SO 7 5 medium control 19.0 18.0 
P014 7 control control 30.5 30.0 
144 6 control control 26.0 30.0 
262 14 control control 22.0 24.0 
P023 7 control control 30.5 34.0 
P018 7 control control 19.0 17.0 
P019 7 control control 17.0 15.0 
S61 5 medium control 27.0 27.0 
SI 3 5 medium control 18.5 18.0 
U03 5 medium control 19.0 17.0 
X04 3 medium control 23.0 24.0 
150 6 control control 21.0 22.0 
155 6 control control 26.0 26.0 
S23 5 high control 23.0 21.0 
UIO 4 high control 27.0 28.0 
S34 5 high control 20.0 20.5 
P036 6 high control 26.0 25.0 
P035 6 high control 20.0 19.0 
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mibolerone and ethanol solution at that time. The intial 
weight of each beagle and the weight at the end of the six-
week treatment period are also reported in Table 2. Over­
all, the mean body weight change, after six weeks of treatment, 
was -0.34 pounds for mibolerone treated beagles and +0.05 
pounds for the control beagles. 
The initial analysis of variance evaluated differences 
in body weight changes, after six weeks, between the mibo­
lerone treated and control treated females. The following 
results were obtained: 
Degrees of Sum of Mean F-
Source freedom squares square value 
Treatment 1 1.36 1.36 0.57 
Error 33 79.31 2.40 
TOTAL 34 80.67 
These results indicate there was no significant (P<0.05) 
difference in body weight gain or loss between mibolerone 
treated and control treated female beagles. 
Analysis of variance comparing the effect of the treat­
ment, dietary protein level and the treatment and dietary 
protein level interaction provided the following results; 
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Source 
Model 
Error 
TOTAL 
Degrees of 
freedom 
5 
29 
34 
Sum of Mean 
squares square 
17.70 
62.97 
80.67 
3.54 
2.17 
F-
value 
1.63 
Treatment 
Diet 
Treatment-Diet 
Interaction 
1 
2 
1.36 1.36 
2.69 1.34 
13.65 6.82 
0.63 
0.62 
3.14 
The dietary protein level and/or the treatment-diet inter­
action did not significantly (P<0.05) effect body weight. 
Treatment and age and a treatment-age interaction were 
analyzed with an analysis of variance, and the following 
results were obtained: 
Source 
Model 
Error 
TOTAL 
Degrees of 
freedom 
12 
22 
34 
Sum of 
squares 
26.46 
54.21 
80.67 
Mean F-
square value 
2.20 
2.46 
0.89 
Treatment 
Age 
Treatment-age 
Interaction 
1 
7 
1.36 
20.26 
4.83 
1.36 0.55 
2.89 1.17 
1.21 0.49 
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The results indicate that treatment and age or a treatment-
age interaction had no significant (P<0.05) effect on body 
weight. 
Cystoscopic Examination of 
the Vagina 
A gross vaginal examination, with a cystoscope, was 
performed on three female beagles four weeks after the 
delivery device had been inserted. The vaginal canal ap­
peared grossly normal in each beagle and it was noted that 
there was no excessive exudate, inflammation or hyperemia 
present (Figure 12). Following the delivery device removal, 
there was a small amount of bleeding into the vaginal lumen 
of two females. This bleeding was thought to be caused by 
the examination and delivery device removal procedures. 
Mibolerone Radioimmunoassay 
Mibolerone was detected in none of the 98 plasma 
samples which were assayed. The radioimmunoassay used in this 
study had a lower range of sensitivity of 1.8 parts per 
billion. 
Figure 12. A view within the vaginal canal of Beagle X03, 
4 weeks after delivery device insertion (note -
no excessive exudate, inflammation or hyperemia) 
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Monitoring During Treatment to Determine 
the Phase of the Estrous Cycle 
Progesterone levels, vaginal cell smears and discharge 
and vulvar swelling were monitored during the treatment 
period to ascertain estrous phase for each animal during the 
treatment period. 
Radioimmunoassay for progesterone was completed on 204 
plasma samples (Table 3). The majority of these samples 
were from females that were treated with mibolerone re­
leased by the delivery device. The original intention was 
to assay the plasma samples of the five control treated 
beagles during diestrus; however, one sample was mis­
takenly taken when the animal was in late estrus. The beagle 
(P036) in late estrus had 9.18 ng progesterone/ml of plasma. 
The 4 diestrual beagles (P023, S61, S42 and S43) had a mean 
peak of 24.7 ng progesterone/ml of plasma. The progesterone 
levels in most of the females treated with the mibolerone 
remained at levels expected during anestrus (0.0 ng to 1.0 
ng/ml of plasma). However, 3 of the beagles (POll, U06 
and X02) treated with mibolerone had an unexpected rise in 
progesterone level during the treatment period (Table 3 and 
Figure 13). The rise in progesterone level in these 3 
animals did not attain the levels normally seen during 
diestrus but averaged 7.4 ng progesterone/ml of plasma at 
their peak. The vaginal cell smears for these 3 animals 
Figure 13. Plasma progesterone levels during treatment 
(Control - illustrates the normal expected plasma progesterone level 
increases during estrus and diestrus, 
Group A - were drug treated animals (n=12) which demonstrated no 
increases in progesterone levels during the treatment 
period. 
Group B - were drug treated animals (POll, U06 and X02) which 
demonstrated some increase in progesterone levels during 
the treatment period. 
Note - Groups A and B demonstrated no vaginal discharges and the 
vaginal smears indicated anestrus during the treatment 
period) 
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(0 E 
w 30 (S 
z 
Ë 
0) 20 c o L. 
« 4-< (A 10 
« 0) 
2 
CL 0 
O) c 
• Control 
• Group B 
A Group A 
Estrus 
-10 10 20 30 40 50 60 70 80 
Days 
65 
Table 3. Progesterone levels and phase of the estrous cycle 
Beagle Date 
ng progesterone/ 
ml of plasma 
Estrous cycle stage as 
indicated by vaginal 
cell smear 
218 02-15-78 0.37 Treatment begun Anestrus 
03-01-78 TLH* Anestrus 
03-15-78 TLH Anestrus 
03-16-78 Expected estrus 
03-29-78 TLH Anestrus 
04-12-78 TLH Anestrus 
04—26—78 TLH Anestrus 
05-10-78 TLH Treatment stop Anestrus 
01-03-79 16.50 Late estrus 
427 02-15-78 TLH Treatment begun 
03-01-78 TLH 
03-15-78 TLH 
03-20-78 Expected estrus 
03-29-78 TLH 
04-12-78 TLH 
04-26-78 TLH 
05-10-78 TLH Treatment stop 
05-24-78 TLH 
06-07-78 TLH 
06-21-78 19.55 
07-05-78 26.03 
07-19-78 12.31 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Proestrus 
Diestrus 
Diestrus 
Diestrus 
01-03-79 29.83 Diestrus 
02-15-78 0.28 Treatment begun Anestrus 
03-01-78 TLH Anestrus 
03-15-78 TLH Anestrus 
03-17-78 Expected estrus 
03-29-78 TLH Anestrus 
04-12-78 TLH Anestrus 
04-26-78 TLH Anestrus 
05-10-78 TLH Treatment stop Anestrus 
05-24-78 TLH Anestrus 
06-07-78 TLH Anestrus 
06-21-78 TLH Anestrus 
07-05-78 1.92 Estrus 
867 
12-20-78 35.36 Diestrus 
^TLH = too little hormone, meaning that less than 0.25 ng/ml was 
present. 
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Table 3 (Continued) 
Beagle Date ng progesterone/ 
ml of plasma 
Estrous cycle stage as 
indicated by vaginal 
cell smear 
S62 05-10-78 TLH Treatment begun Anestrus 
05-24-78 TLH Anestrus 
06-07-78 TLH Anestrus 
06-20-78 Expected estrus 
06-21-78 TLH Anestrus 
07-05-78 TLH Anestrus 
07-19-78 TLH Anestrus 
08-02-78 TLH Treatment stop Anestrus 
08-15-78 TLH Anestrus 00 1 0 
ro 1 0
0 o
 0.88 Anestrus 
09-13-78 11.24 Estrus 
09-27-78 19.14 Diestrus 
03-08-79 22.92 Diestrus 
YQll 05-24-78 TLH Treatment begun 
06-07-78 TLH 
06-21-78 TLH 
06-30-78 Expected estrus 
07-05-78 0.30 
07-19-78 TLH 
08-02-78 TLH 
08-15-78 TLH Treatment stop 
08-30-78 0.34 
09-13-78 18.82 . 
09-27-78 16.43 
10-11-78 20.53 
Anestrus 
Ane s tr us 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Metestrus 
Diestrus 
Diestrus 
- Late estrus 
03-08-79 2.38 Early estrus 
03-22-79 23.18 Diestrus 
PQY2 04-24-78 TLH Treatment begun Anestrus 
06-07-78 TLH Anestrus 
06-21-78 TLH Anestrus 
06-28-78 TLH Anestrus 
06-28-78 Expected estrus 
07-05-78 TLH Anestrus 
07-19-78 TLH Anestrus 
08-02-78 TLH Anestrus 
08-15-78 TLH Treatment stop Anestrus 
08-30-78 0.33 Anestrus 
09-13-78 15.29 Estrus 
09-27-78 18.84 Diestrus 
10-11-78 7.87 Diestrus 
10-25-78 TLH Anestrus 
12-06-78 27,28 Diestrus 
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Table 3 (Continued) 
Beagle Date ng progesterone/ 
ml of plasma 
Estrous cycle stage as 
indicated by vaginal 
cell smear 
VDU3 05-24-78 TLH Treatment begun Anestrus 
06-07—78 TLH Anestrus 
06-21—78 TLH Anestrus 
07-05-78 TLH Anestrus 
07-07-78 Expected estrus 
07-19-78 TLH Anestrus 
08-02-78 TLH Anestrus 
08-15-78 TLH Treatment stop Anestrus 
08-30-78 TLH Anestrus 
09-13-78 TLH Anestrus 
09-27-78 TLH Anestrus 
11-18-78 Estrus 
12-06-78 22.32 Diestrus 
S57 09-13-78 TLH Treatment begun Anestrus 
09-27-78 1.43 Anestrus 
09-30-78 Expected estrus 
10-11-78 TLH Anestrus 
10-25-78 TLH Anestrus 
11-07-78 TLH Anestrus 
11-22-78 TLH Anestrus 
12-06-78 TLH Treatment stop Anestrus 
12-20-78 TLH Anestrus 
01-03-79 TLH Anestrus 
01-19-79 3.92 Late proestrus 
poll 09-27-78 TLH Treatment begun Anestrus 
10-11-78 TLH Anestrus 
10-15-78 Expected estrus 
10-25-78 TLH Anestrus 
11-07-78 TLH Anestrus 
11-22-78 5.53 Anestrus 
12-06-78 6.74 Anestrus 
12-20-78 6.63 Treatment stop Anestrus 
01-03-79 2.38 Anestrus 
01-19-79 Anestrus 
01-31-79 1.74 Anestrus 
10-20-79 Estrus 
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Table 3 (Continued) 
Beagle Date ng progesterone/ 
ml of plasma 
Estrous cycle stage as 
indicated by vaginal 
cell smear 
S54 09-27-78 0.39 Treatment begun Anestrus 
10-11-78 TLH Anestrus 
10-25-78 TLH Anestrus 
11—06—78 Expected estrus 
11-07-78 TLH Anestrus 
11-22-78 TLH Anestrus 
12-06-78 TLH Anestrus 
12-20-78 TLH Treatment stop Anestrus 
01-03-79 TLH Anestrus 
01-19-79 0.35 Early proestrus 
01-31-79 26.42 Diestrus 
U17 09-27-78 TLH Treatment begun Anestrus 
10-11-78 TLH Anestrus 
10-20-78 Expected estrus 
10-25-78 TLH Anestrus 
11-07-78 0.29 Anestrus 
11-22-78 0.25 Anestrus 
12—05—78 TLH Anestrus 
12-20-78 TLH Treatment stop Anestrus 
01-03-79 TLH Anestrus 
01-19-79 1.40 Proestrus 
01-31-79 24.47 Diestrus 
02-15-79 19.17 Diestrus 
U06 02-15-79 TLH Treatment begun Anestrus 
03-08-79 TLH Anestrus 
03-20-79 Expected estrus 
03-22-79 8.58 Anestrus 
04-05-79 11.19 Anestrus 
04-17-79 6.86 Anestrus 
05-02-79 2.22 Anestrus 
05-16-79 0.90 Treatment stop Anestrus 
06—04—79 TLH Anestrus 
06-13-79 TLH Anestrus 
06-27-79 TLH Anestrus 
U09 03-08-79 0.56 Treatment begun 
03-22-79 TLH 
04-05-79 TLH 
04-10-79 Expected estrus 
04-17-79 TLH 
05-02-79 TLH 
05-16-79 TLH 
06-04-79 TLH Treatment stop 
06-13-79 TLH 
06-27-79 TLH 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
Anestrus 
07-25-79 Estrus 
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Table 3 (Continued) 
Beagle Date ng progesterone/ 
ml of plasma 
Estrous cycle stage as 
indicated by vaginal 
cell smear 
X02 03-08-79 TLH Treatment begun Anestrus 
03-22-79 2.33 Anestrus 
04-01-79 Expected estrus 
04-05-79 4.40 Anestrus 
04-17-79 3.71 Anestrus 
05-02-79 2.62 Anestrus 
05-15-79 1.71 Anestrus 
06-04-79 TLH Treatment stop Anestrus 
06-13-79 TLH Anestrus 
06-27-79 TLH Anestrus 
X03 03-08-79 TLH Treatment begun Anestrus 
03-22-79 TLH Anestrus 
04-01-79 Expected estrus 
04-05-79 TLH Anestrus 
04-17-79 TLH Anestrus 
05-02-79 TLH Anestrus 
05-16-79 TLH Anestrus 
06-04-79 TLH Treatment stop Anestrus 
06—13—79 TLH Anestrus 
06-27-79 TLH Anestrus 
09-16-79 Estrus 
P023 05-20-79 Expected estrus 
06—04—79 25.34 Diestrus 
07-19-79 16.46 Diestrus 
S61 07-29-78 Expected estrus 
08-15-78 31.43 Diestrus 
542 04-12-78 
05-02-78 
TLH 
Expected estrus 
Anestrus 
05-10-78 20.14 Diestrus 
05-24-78 23.63 Diestrus 
12-06-78 TLH Anestrus 
12-17-78 Expected estrus 
12-20-78 11.20 Estrus 
S43 12-06-78 
12-12-78 
18.33 
Expected estrus 
Metestrus - Early Diestrus 
P036 09-27-78 
10-05-78 
TLH 
Expected estrus 
Anestrus 
10-11-78 9.18 Estrus 
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indicated an anestrus condition during this same period of 
progesterone elevation (Table 3). Also, gross examination 
during this same period revealed no vulvar swelling and no 
vaginal discharge. The vaginal smears, vulvar swellings 
and discharges for the control animals were in agreement 
with progesterone levels. 
Gross Examination for 
Mibolerone Overdose 
The mibolerone treated animals were examined daily for 
the presence of ocular and vaginal discharges and clitoral 
enlargement, phenomena which are known to be associated with 
a mibolerone overdose. Ocular discharge was occasionally 
seen in many of the beagles, treated and nontreated, which 
made it impossible to determine if the discharge was 
mibolerone related. Vaginal discharge and clitoral enlarge­
ment were not seen throughout the treatment period in animals 
treated with mibolerone. The general appearance of the vulva 
of two beagles, after six weeks of mibolerone treatment, can 
be seen in Figures 14 and 15. 
Figure 14. Beagle VDU3 illustrates the appearance of the 
vulva 6 weeks after the delivery device was 
inserted (note - no vaginal discharge) 
Figure 15. Beagle POll illustrates the appearance of the 
vulva 6 weeks after the delivery device was 
inserted (note - no vaginal discharge) 
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Statistical Analysis of 
Progesterone Levels 
A statistical analysis of progesterone levels did indi­
cate a significant (P<0.001) difference in progesterone level 
means between the mibolerone treated and control beagles. 
(The calculations are reported in Table 4). The mean pro­
gesterone level for mibolerone treated females (during the 
Table 4. Calculations for the statistical analysis of 
progesterone levels 
Mibolerone Control 
treated treated 
animals (m) animals (c) 
n = 15 4 
Totals Ex = 27.20 98.73 
Means (X) = 1.81 24.68 
= 193.20 2,524.33 
(ZX)2/n = 49.32 2,436.90 
Sum of Squares =EX^ - (EX) ^/n = 143.88 87.43 
Degrees of freedom n-1 = 14 3 
Pooled sample variance = 
4 + "c 
13.61 
Standard deviation _ 
between means X -
m 
2.08 
n +n 
Calculated Vt' = ° 9.13 
Table 't' value (P<0.001) = 3.96 
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treatment period) was 1.81 ng progesterone/ml of plasma and 
for control beagles was 24.68 ng progesterone/ml of plasma. 
The calculated t-value was 9.13 with 17 degrees of freedom 
and the table t-value was 3.96 (at P<0.001). 
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DISCUSSION 
Intravaginal Drug Delivery for 
Estrus Control 
The intravaginal route for delivering estrus controlling 
drugs has not been previously utilized in the canine. One 
reason this route may have been avoided by other investi­
gators is that they may have had problems retaining an 
intravaginal device. In this study there was 100% retention 
of all delivery devices tested. The silastic "fingers" of 
the delivery device provided a very simple and satisfactory 
means of retaining the device within the vaginal canal of 
the beagle. Unfortunately, this same retaining design may 
not be applicable to animals other than the canine. 
Unlike the ABC device (Hauge, 1974), the delivery 
device for the present study was neither designed nor intended 
to prevent penile insertion. Possibly, the intravaginal 
delivery device may hinder penile insertion, but it probably 
will not prevent it. 
Cystoscopic Examination of 
the Vagina 
Inflammation and infection are risks whenever a foreign 
body is placed in the vagina. For the present study, a 
medical grade silastic tubing was selected specifically to 
cover the delivery device in order to minimize the possibility 
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of intravaginal inflammation or infection. 
Six of the beagles (427, 218, 867, PQY2, YQIl and U06) 
receiving delivery devices had an occasional slight vaginal 
discharge during the first 2 weeks after device insertion. 
The vaginal discharges were serosanguineous, all of which 
cleared by the third week after delivery device insertion. 
Three females had delivery devices re-inserted into the 
vaginal canal in order to gain an insight into the gross 
effect of the delivery device upon the vaginal mucosa. 
Delivery devices were re-inserted into the vagina of fe­
males U09 and X03, 6 months after the original treatment 
study. The devices remained intravaginally 4 weeks before 
the vaginal examination with the cystoscope. Another beagle 
(X02) had the delivery device re-inserted intravaginally 
7 months after the mibolerone treatment and was examined 
with the cystoscope 3 weeks later. Beagle X0 3 did have a 
slight serosanguineous vaginal discharge for the first few 
days after the delivery device was re-inserted. Upon 
examination, no females were found to have excessive 
exudate, inflammation or vaginal bleeding. A view of 
the vaginal mucosa of beagle X02 can be seen in Figure 12. 
The conclusion is that the delivery device was com­
patible with the vaginal mucosa, after a 2 to 3 week adjust­
ment period, for the duration of this study. 
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Mibolerone Radioimmunoassay 
The radioimmunoassay of the plasma samples for the 
presence of mibolerone was done with some expectation that 
an insight into the delivery rate for mibolerone would be 
gained. Unfortunately, mibolerone was undetectable in the 
plasma samples from the test females. The fact that 
mibolerone was undetected in the plasma is not alarming be­
cause in tests performed at the Upjohn Company it was proven 
that when mibolerone was mixed with food, estrus was pre-
1 
vented even though mibolerone was not detected in the plasma . 
The assay sensitivity, 1.8 parts per billion, for the present 
study, was insufficient to detect an effective dose of 
the mibolerone. 
Drug Diffusion Rate of the 
Delivery Device 
Diffusion rate for mibolerone across a silastic mem­
brane was not known at the beginning of this study. A 
calculated estimate for the daily dosage of mibolerone was 
based on the known diffusion rate for testosterone (Simmons 
and Hamner, 19 73) . The initial daily dosage of mibolerone 
was set to theoretically deliver 60 yg/day, which is double 
the recommended oral dose for preventing estrus in the 
^Jenaay M. Brown, D.V.M., Reproduction Research, The 
Upjohn Company, Kalamazoo, Michigan. 
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beagle. The delivery devices were filled with enough of the 
ethanol-mibolerone mixture to deliver for approximately 5 
months at 60 ]jg of mibolerone/day. All delivery devices 
were empty of ethanol when removed at 3 months, but 
delivery devices (3) visually inspected at the end of 10 
weeks had approximately 0.1 ml of ethanol remaining. The 
delivery devices were disassembled and dried after removal 
from each animal. The devices then were visually inspected 
for the presence, of mibolerone crystals in the drug chamber. 
The fact that no delivery device appeared to contain mibo­
lerone crystals indicates that mibolerone diffusion rate 
exceeded 60 yg/day. 
Gross Examination for 
Mibolerone Overdose 
The delivery device may have been delivering a daily 
dosage greater than 60 yg of mibolerone/day, in which case 
some overdose effects could be expected. But clitoral en­
largement, ocular and vaginal discharges, all known over­
dose effects, did not occur among any of the treated ani­
mals. The fact that these symptoms were not present could 
mean that a higher dosage than what is required by oral dose 
may be necessary for effectiveness by this route. It may 
also mean that a higher than normal dosage can be given 
intravaginally without eliciting an overdose response. 
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Estrus Resumption after 
Treatment 
All females resumed normal estrous cycles following 
cessation of the intravaginal treatment with mibolerone. 
The time lapse following delivery device removal until the 
next estrus varied with each animal. Estrus was observed 
to recur 14 days to 238 days after treatment with mibo­
lerone was discontinued. These results are consistent with 
reported observations of other investigators (Sokolowski 
and Ceng, 1977). 
Body Weight 
The use of anabolic steroids has been known to cause 
an increased appetite with a corresponding increase in food 
consumption resulting in an increase in body weight. No 
significant (P<0.05) weight differences between the animals 
treated with mibolerone and untreated animals could be 
determined in the present study. But long term mibolerone 
treatment effects on weight gain can not be evaluated 
here and it is possible that weight gains may occur with 
prolonged treatment. 
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Monitoring During Treatment to Determine 
the Phase of the Estrous Cycle 
Normally, the canine experiences estrus either during 
or about the same time that the plasma progesterone levels 
increase (Figure 13). There were alterations in the normally 
expected progesterone levels for proestrus, estrus and 
diestrus in the mibolerone treated animals. The progesterone 
levels of 12 mibolerone treated beagles remained at the low 
levels normally seen in anestrus (0.0 yg to 1.0 yg/ml of 
plasma) during the test period in which estrus was expected 
to occur. In addition, mibolerone treated females (X02, 
U06 and POll) which did have increases in progesterone levels 
during the test period did not exhibit the progesterone in­
creases normally expected during diestrus (Figure 13). A 
study conducted within the Upjohn Company (Reimers, 1978) 
indicated that similar progesterone increases may have 
occurred in mibolerone treated female beagles they were 
testing. However, very little data were published, so 
complete comparisons are not possible. The most practical 
explanation for the observed increases in progesterone 
levels, for beagles X02, U06 and POll, must be based upon 
follicular development. Low level progesterone production 
begins with secondary follicular development in the ovary. 
It is assumed that these 3 beagles (X02, U06.and POll) underwent 
secondary follicular development, began producing progesterone. 
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but never ovulated. The anovular (atretic) follicles then 
began degenerating without the normal corpora lutea de­
veloping, which prevented the normal increases in plasma 
progesterone levels from being observed. Instead, the 
lower than normal plasma progesterone levels were produced 
from the degenerating anovular follicles. 
Gross examination for vulvar swelling and vaginal 
discharge did not indicate proestrus or estrus for mibolerone 
treated animals during the treatment period. Also, the 
vaginal smears taken during this same period indicated an 
anestrus condition (Table 3). The fact that no mibolerone 
treated beagle demonstrated behavioral receptivity, normally 
seen during estrus, further indicates that "true" estrus 
did not occur during the treatment period. 
The statistical analysis has indicated a significant 
(P<0.001) difference between the progesterone level means 
of the mibolerone treated and the nontreated beagles. This, 
then, implies that the intravaginal drug delivery device 
did provide an adequate daily dosage of mibolerone to pre­
vent estrus from occurring throughout the test period. 
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Delivery Device Internal 
Pressure 
The delivery device designed for this study was unique 
in that it used a spring to create a positive pressure 
(Figure 1). The main purpose for having a high internal 
pressure (Table 1) within the delivery device was to mini­
mize the effect of diffusion into the drug chamber from 
the vaginal canal. In the present study, the osmotic and 
intravaginal pressures outside the silastic membrane were 
thought to be very small. The fact that the delivery device 
contained 0.8 ml of the ethanol-mibolerone solution initially 
and appeared completely void of all materials at the end of 
the treatment, suggests that the delivery device internal 
pressure was great enough to predominate osmotic and mechani­
cal pressures which were encountered in the vaginal canal. 
In addition, the spring tension may be adjusted to 
allow for some control of the ethanol-mibolerone flow rate. 
For example, if the membrane were thought of as a porous 
system and the flow of a solution through each pore were 
described by Poiseuille's law, then; 
NïïE iP 0 = -w:— 
Where Q = flow (in ml/min), when N = the number of pores in 
the membrane; R = the radius of the pore in cm; AP = the 
pressure change in mm Hg (across the membrane); n = the 
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viscosity of solution in poise; and, L = the thickness of 
the membrane in cm. For this formula it is necessary to con­
vert units if we want the final units for Q to be in ml/min. 
So, if K represents the conversion of units to derive ml/min, 
then : 
= KNR AP and K = 31413. 
r|L 
Now, using selected theoretical values, the following flow 
rates may be calculated; 
Whereas, a AP of 400 mm Hg, and all other values the same, 
would provide ; 
And, if AP was 8 00 mm Hg then; 
Therefore, theoretically, the delivery device created for 
this study would have delivered 30 yg of mibolerone/day if 
the ethanol-mibolerone solution flow rate was adjusted for 
-5 1 X 10 ml/min. 
The previously mentioned equation was utilized to 
illustrate the effect of pressure as it acts on molecules 
crossing a membrane. The equation was designed to fit a 
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porous membrane and silastic membranes, strictly defined, 
do not have pores or openings. 
Alternative Means for 
Dispensing Drugs 
Other pressure creating means for drug dispensation may 
have been used in the delivery device developed for the 
present study. An expandable material present in both the 
liquid and gas form could be contained in the chamber behind 
the plunger of the delivery device; for example, a fluoro-
carbon in a liquid-vapor combination has served as a 
propellant in a delivery device (Blackshear, 1979). A 
liquid in equilibrium with its vapor phase exerts a constant 
vapor pressure at a given temperature, even though the volume 
may change. A disadvantage of the liquid-vapor pressure 
method is its sensitivity to temperature changes. The liquid-
vapor must be injected into the pressure chamber of the 
delivery device under pressure and adjusted outside the 
animal to deliver at body temperature and pressure within the 
animal. 
The use of a fixed charge of compressed air or other 
gas to create a pressure behind the pluhger (Figure 1) 
would not provide a constant delivery rate. A volume 
increase in the pressure chamber behind the plunger would 
result in a decrease in pressure and result in changes in 
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the drug flow rate. 
Delivery devices using an osmotic chamber saturated with 
a drug rely on an osmotic pressure gradient for the drug 
transport. The drug is transported from the osmotic 
chamber through a flow moderator (capillary tube) which is 
of a specific size to deliver a set amount of the drug when 
operating at a maximum flow rate. The osmotic chamber must 
be saturated with an excess of the drug. The author has not 
seen any published data that will support the fact that this 
type of an implantable device has been used to deliver a drug 
beyond a period of two weeks. 
Ethanol and Mibolerone Concentration 
within the Delivery Device 
Presently it is believed that the linear pressure of 
the spring on the plunger within the delivery device helps 
maintain a relatively constant concentration of mibolerone 
in ethanol. This is accomplished by the fact that as 
the ethanol-mibolerone solution diffuses out, the linear pres­
sure of the spring moves the plunger forward maintaining a 
relatively constant ethanol and mibolerone ratio within 
the solution. But, in order for the constant concentration 
to be maintained, the diffusing volume ratio of ethanol 
to mibolerone had to remain constant, even though 
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it is probable that ethanol and mibolerone do neither diffuse 
bound together nor at the same rate across the silastic 
membrane. It is believed that the present delivery device 
parameters permitted the diffusing volume ratio of ethanol 
to mibolerone to remain rather constant throughout the 
treatment period. This is supported by the fact that both 
the ethanol and mibolerone were gone from the delivery 
device at 3 months and estrus was suppressed during the 
treatment period. 
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CONCLUSIONS 
From this study, the following conclusions can be drawn: 
1) Mibolerone delivered intravaginally did inhibit estrus 
in beagles; 2) the slow releasing delivery device was 
successful in delivering mibolerone and it was compatible 
with placement in the vaginal canal; and, 3) it is believed 
that the delivery device could provide an economical, non­
surgical, reversible means of preventing estrus in the 
female canine. 
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APPENDIX A; ASSIMILATED PLASMA LEVELS FROM 
ASSORTED SOURCES 
The graph presented here, depicts the normally expected 
hormone levels for LH, progesterone and estrogen during 
proestrus, estrus and diestrus in the bitch. 
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Normally expected hormone levels for LH, progesterone and estrogen 
during proestrus, estrus and diestrus in the bitch 
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APPENDIX B; PROGESTERONE RADIOIMMUNOASSAY 
PROCEDURE 
The following is a step by step procedure for the pro 
gesterone radioimmunoassay used in this study. 
Extraction of the plasma; 
1) Use a 16 mm by 125 mm test tube with cap. 
2) Sample 100 yl of plasma (100% on the 100 pi pump) 
and flush with 400 yl of Tris buffer (40% on the 
1 ml pump). 
3) Add 4.5 ml of petroleum ether. 
4) Cap tightly and shake for 15 minutes. 
5) Place the test tubes in a bath of dry ice-methanol 
solution until the water layer freezes (or in the 
freezer overnight). 
6) Pour off the petroleum ether phase of each sample 
into a 12 mm by 75. mm test, tube. 
7) Evaporate off the petroleum ether under air in a 
40*C water bath. 
8) Add 100 yl of Tris buffer to all test tubes (50% on 
the 200 yl pump). 
9) Vortex vigorously. 
The set-up of standard curve tubes; 
1) Use 12 by 75 tubes. 
2) With a Pipetman add: 
Tube 1-Nonspecific binding (NSB) 0 .5 ml Tris buffer 
Tube 2-Total 0 .7 ml Tris buffer 
Tube 3-0 progesterone 0 .1 ml Tris buffer 
Tube 4-25 ng of progesterone 0 .1 ml of the ap-
propriate standard 
I I  
I I  
Tube 11-3200 ng of progesterone " 
3) With the Pipetman, add 0.1 ml tracer to tubes 1 and 
2 .  
100 
Assay; 
1) Make up the antibody in 1:25,000 dilution. Antibody 
is already diluted 1:1,000 and kept in the freezer 
in 2 ml aliquots. For one assay, add 48-50 ml of 
Tris buffer to the 2 ml of antibody. 
2) Add antibody and the tracer simultaneously by Micro-
medic pipette to all tubes, excluding 1 and 2. 
(Antibody, 0.4 ml = 40% on the 1 ml pump and tracer, 
0.1 ml = 50% on the 200 ul pump.) 
3) Vortex gently and then cover with parafilm. 
4) Incubate overnight in the cold room or 1 hour at 
room temperature and 1 hour in the cold room. 
Termination of the assay; 
1) Stir charcoal-dextran for about 15 minutes in the 
cold room before using. 
2) Set timer for 15 minutes. Add 0.2 ml of the charcoal-
dextran to all tubes, except the total tube (tube 
#2) and with the standard curve tubes in the middle 
of the sample tubes. 
3) Vortex all tubes. 
4) 15 minutes after addition of the charcoal-dextran to 
the first tube, centrifuge all tubes at 3000 rpm 
for 10 minutes. 
5) Sample 0.5 ml of the assay supernatant (50% on the 
1 ml pump) and flush with 4.5 ml of scintillation 
cocktail (90% on the 5 ml pump) into bantam vials. 
6) Count on the tritium channel of the liquid scintal-
lator for 2 or 4 minutes. 
(Note - 120 test tubes could be processed at one time, 
the standard curve needed 11 x 2 = 22 tubes, so 98 
tubes were available for samples. There were 49 
samples processed in duplicate.) 
The progesterone standard; 
1) Weigi\ 10 mg P4 and add to 10 ml methanol to make 
1 mg/ml. Use a volumetric flask. 
2) Dilute 1:100 
100 ul is added to 10 ml of methanol, making 10 
jig/ml. Use a 100 yl Hamilton and volumetric flask. 
3) Dilute 1:40 
250 yl of #2 is added to 10 ml of Tris buffer, 
making 250 ng/ml. Use a 500 yl Hamilton and 
volumetric flask. 
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4) Working dilutions; 
250 ng/ml Tris conc. conc. 
stock Method buffer pg/ml in 0.1 ml 
15 ]xl 50 yl 15 ml 250 25 pg 
30 ]il 50 yl H 15 ml 500 50 pg 
60 Kl 100 yl H 15 ml 1000 100 pg 
120 yl 500 yl H 14.9 ml 2000 200 pg 
240 yl 500 yl H 14,8 ml 4000 400 pg 
480 ill 500 yl H 14.5 ml 8000 800 pg 
960 yl 1 ml pipet. 14.0 ml 16000 1600 pg 
1.92 ml 2 ml pipet. 13.1 ml 32000 3200 pg 
3 
Tracer progesterone (1,2,6, 7(n)- H progesterone); 
Specific activity was 303 mCi/mg. To determine the 
number of pg placed in each sample tube, the following calcu­
lations were necessary: 
6 9 2.2 X 10 dpm/v»Ci x 1000 yCi/mCi = 2.2 x 10^ dpm/mCi. 
Q Q 
2.2 X 10 dpm/mCi x 330 mCi/mg = 666 x 10 dpm/mg = 
666 X 10^ dpm/yg = 666 x 10^ dpm/ng = 666 dpm/pg 
For dilution; 
1 mCi/ml to 10 ml = 0.1 mCi/ml of stock solution. 
0.1 mCi/ml x 0.2 ml = 0.02 mCi; put this in 100 ml 
buffer. _. 
0.02 mCi/100 ml = 2 x 10 mCi/ml and a 0.1 ml sample 
of this gives 2 x 10~5 mCi. . 
2.2 X 10^ dpm/mCi x 2 x 10-5 mCi = 4.4 x 10 dpm or 
44,000 dpm in each tube or about 20,000 cpm. 
gëÔ°dpm%g = M each tube. 
Could try putting the 200 pi of stock in 150 ml of Tris 
buffer. 
0.02 mCi/150 ml = 1.3 x lO"* mCi/ml. 
0.1 ml contains 1.3 x 10"® mCi. 
2.2 X 10^ dpm/mCixl.3 x 10 ^ mCi =2.9 x 10^ dpm 
or 29,000 dpm in each tube or about 15,000 cpm. 
29,000 dpm .. . . . . 6iO apm/pg = " each tube. 
'Hamilton flask. 
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Tris buffer: 
0.01 M Tris 
0.1% gelatin 
1:10,000 Merthiolate pH 7.4 
To make 2 liters; 
1) 2.4228 g Tris in 1500 ml H2O in beaker. 
2) Add 2 ml merthiolate (1:10). 
3) Bring to pH 7.4 with 5 N HCl. 
4) Bring to 2 liter volume in a volumetric flask 
and then pour back into the beaker. 
5) Add 2 g gelatin and stir for 30 minutes with 
heater at 2 or 3 until gelatin dissolves. 
Merthiolate stock solution 1:10: 
4 g merthiolate added to 40 ml of HgO. 
Charcoal-dextran: 
1) 6.25 g charcoal added to 0.625 g dextran g dextran 
T-70 in 500 ml of H2O. 
2) Stir for 8 hours in the cold (a cold room). 
Scintillation cocktail; 
Triton-X-100 1100 ml 
Toluene 2500 ml 
PPO 14.5 g 
POPOP 0.362 g 
